Copyright Reports & Markets. All rights reserved.

Global Gynecological Cancers Therapeutics Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Gynecological Cancers Therapeutics Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Cervical Cancer
      • 1.4.3 Ovarian Cancer
      • 1.4.4 Endometrial Cancer
      • 1.4.5 Vaginal Cancer
      • 1.4.6 Vulvar Cancer
      • 1.4.7 Other
    • 1.5 Market by Application
      • 1.5.1 Global Gynecological Cancers Therapeutics Market Share by Application (2019-2025)
      • 1.5.2 Targeted Therapy
      • 1.5.3 Chemotherapy
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Gynecological Cancers Therapeutics Market Size
    • 2.2 Gynecological Cancers Therapeutics Growth Trends by Regions
      • 2.2.1 Gynecological Cancers Therapeutics Market Size by Regions (2019-2025)
      • 2.2.2 Gynecological Cancers Therapeutics Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Gynecological Cancers Therapeutics Market Size by by Players
      • 3.1.1 Global Gynecological Cancers Therapeutics Revenue by by Players (2014-2019)
      • 3.1.2 Global Gynecological Cancers Therapeutics Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Gynecological Cancers Therapeutics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Gynecological Cancers Therapeutics Key Players Head office and Area Served
    • 3.3 Key Players Gynecological Cancers Therapeutics Product/Solution/Service
    • 3.4 Date of Enter into Gynecological Cancers Therapeutics Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Gynecological Cancers Therapeutics Market Size by Type (2014-2019)
    • 4.2 Global Gynecological Cancers Therapeutics Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Gynecological Cancers Therapeutics Market Size (2014-2019)
    • 5.2 Gynecological Cancers Therapeutics Key Players in North America
    • 5.3 North America Gynecological Cancers Therapeutics Market Size by Type
    • 5.4 North America Gynecological Cancers Therapeutics Market Size by Application

    6 Europe

    • 6.1 Europe Gynecological Cancers Therapeutics Market Size (2014-2019)
    • 6.2 Gynecological Cancers Therapeutics Key Players in Europe
    • 6.3 Europe Gynecological Cancers Therapeutics Market Size by Type
    • 6.4 Europe Gynecological Cancers Therapeutics Market Size by Application

    7 China

    • 7.1 China Gynecological Cancers Therapeutics Market Size (2014-2019)
    • 7.2 Gynecological Cancers Therapeutics Key Players in China
    • 7.3 China Gynecological Cancers Therapeutics Market Size by Type
    • 7.4 China Gynecological Cancers Therapeutics Market Size by Application

    8 Japan

    • 8.1 Japan Gynecological Cancers Therapeutics Market Size (2014-2019)
    • 8.2 Gynecological Cancers Therapeutics Key Players in Japan
    • 8.3 Japan Gynecological Cancers Therapeutics Market Size by Type
    • 8.4 Japan Gynecological Cancers Therapeutics Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Gynecological Cancers Therapeutics Market Size (2014-2019)
    • 9.2 Gynecological Cancers Therapeutics Key Players in Southeast Asia
    • 9.3 Southeast Asia Gynecological Cancers Therapeutics Market Size by Type
    • 9.4 Southeast Asia Gynecological Cancers Therapeutics Market Size by Application

    10 India

    • 10.1 India Gynecological Cancers Therapeutics Market Size (2014-2019)
    • 10.2 Gynecological Cancers Therapeutics Key Players in India
    • 10.3 India Gynecological Cancers Therapeutics Market Size by Type
    • 10.4 India Gynecological Cancers Therapeutics Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Gynecological Cancers Therapeutics Market Size (2014-2019)
    • 11.2 Gynecological Cancers Therapeutics Key Players in Central & South America
    • 11.3 Central & South America Gynecological Cancers Therapeutics Market Size by Type
    • 11.4 Central & South America Gynecological Cancers Therapeutics Market Size by Application

    12 International Players Profiles

    • 12.1 AstraZeneca
      • 12.1.1 AstraZeneca Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Gynecological Cancers Therapeutics Introduction
      • 12.1.4 AstraZeneca Revenue in Gynecological Cancers Therapeutics Business (2014-2019))
      • 12.1.5 AstraZeneca Recent Development
    • 12.2 Bristol-Myers Squibb Company
      • 12.2.1 Bristol-Myers Squibb Company Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Gynecological Cancers Therapeutics Introduction
      • 12.2.4 Bristol-Myers Squibb Company Revenue in Gynecological Cancers Therapeutics Business (2014-2019)
      • 12.2.5 Bristol-Myers Squibb Company Recent Development
    • 12.3 F. Hoffmann-La Roche Ltd
      • 12.3.1 F. Hoffmann-La Roche Ltd Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Gynecological Cancers Therapeutics Introduction
      • 12.3.4 F. Hoffmann-La Roche Ltd Revenue in Gynecological Cancers Therapeutics Business (2014-2019)
      • 12.3.5 F. Hoffmann-La Roche Ltd Recent Development
    • 12.4 GlaxoSmithKline plc
      • 12.4.1 GlaxoSmithKline plc Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Gynecological Cancers Therapeutics Introduction
      • 12.4.4 GlaxoSmithKline plc Revenue in Gynecological Cancers Therapeutics Business (2014-2019)
      • 12.4.5 GlaxoSmithKline plc Recent Development
    • 12.5 Merck & Co., Inc.
      • 12.5.1 Merck & Co., Inc. Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Gynecological Cancers Therapeutics Introduction
      • 12.5.4 Merck & Co., Inc. Revenue in Gynecological Cancers Therapeutics Business (2014-2019)
      • 12.5.5 Merck & Co., Inc. Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Gynecological Cancers Therapeutics refer to differences in incidence, prevalence, and mortality from gynecologic cancers between population groups. The five main types of gynecologic cancer include cervical cancer, ovarian cancer, endometrial cancer, vaginal cancer, and vulvar cancer.
      The presence of a strong pipeline and new drug approvals are critical reasons that will drive gynecological cancers therapeutics market growth. The pipeline for gynecological cancers treatment includes novel therapeutics such as targeted therapy products, gene therapy, and vaccines. These products are expected to change the course of gynecological cancer treatment as they are associated with advanced therapeutic mechanisms of action. Some of these mechanisms include cell cycle inhibition, angiogenesis inhibition, programmed death-ligand 1 (PD-L1) inhibition, and PARP inhibition. The approval of novel gynecological cancer therapeutics by the US FDA is increasing due to the efficiency of these drugs.
      In 2018, the global Gynecological Cancers Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Gynecological Cancers Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gynecological Cancers Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      AstraZeneca
      Bristol-Myers Squibb Company
      F. Hoffmann-La Roche Ltd
      GlaxoSmithKline plc
      Merck & Co., Inc.
      ...

      Market segment by Type, the product can be split into
      Cervical Cancer
      Ovarian Cancer
      Endometrial Cancer
      Vaginal Cancer
      Vulvar Cancer
      Other

      Market segment by Application, split into
      Targeted Therapy
      Chemotherapy

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Gynecological Cancers Therapeutics status, future forecast, growth opportunity, key market and key players.
      To present the Gynecological Cancers Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Gynecological Cancers Therapeutics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now